NR1H4 and portal hypertension: We have previously shown that activation of FXR, by 6-ECDCA (INT-747/obeticholic acid) protects against development of portal hypertension in rodent models of liver cirrhosis by reducing liver fibrosis and enhancing, among other mechanisms, the generation of H2S [18, 34–36].